Julien Calderaro

List of Publications by Citations

72 papers	6,381 citations	30 h-index	78 g-index
78 ext. papers	8,488 ext. citations	9.5 avg, IF	5.88 L-index

#	Paper	IF	Citations
72	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nature Genetics*, **2012**, 44, 694-8	36.3	996
71	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nature Genetics*, **2015**, 47, 505-511	36.3	956
70	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. *Nature Communications*, **2013**, 4, 2218	17.4	407
69	Tertiary lymphoid structures in the era of cancer immunotherapy. *Nature Reviews Cancer*, **2019**, 19, 307-325	53.0	397
68	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. *Journal of Hepatology*, **2017**, 67, 727-738	13.4	302
67	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. *Nature Genetics*, **2015**, 47, 1187-93	36.3	290
66	A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. *Gastroenterology*, **2013**, 145, 176-187	13.3	254
65	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. *Hepatology*, **2016**, 64, 2038-2046	11.2	242
64	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. *Hepatology*, **2014**, 60, 1983-92	11.2	202
63	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. *Gastroenterology*, **2017**, 152, 880-894.e6	13.3	198
62	Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. *Cancer Cell*, **2014**, 25, 428-41	24.3	198
61	Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. *Hepatology*, **2011**, 53, 1182-91	11.2	157
60	Genotype-phenotype correlation of CTNNB1 mutations reveals different β-catenin activity associated with liver tumor progression. *Hepatology*, **2016**, 64, 2047-2061	11.2	144
59	Molecular and histological correlations in liver cancer. *Journal of Hepatology*, **2019**, 71, 616-630	13.4	131
58	Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. *Gut*, **2015**, 64, 820-9	19.2	101
57	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. *Journal of Hepatology*, **2019**, 70, 58-65	13.4	86
56	A deep learning model to predict RNA-Seq expression of tumours from whole slide images. *Nature Communications*, **2020**, 11, 3877	17.4	84

55	Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. *Hepatology*, **2018**, 68, 103-112	11.2	83
54	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. *Gastroenterology*, **2019**, 157, 760-776	13.3	77
53	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. *Nature Communications*, **2018**, 9, 5235	17.4	73
52	Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. *Journal of Hepatology*, **2015**, 63, 1173-80	13.4	65
51	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. *Hepatology*, **2020**, 71, 164-182	11.2	62
50	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. *Hepatology*, **2018**, 68, 949-963	11.2	60
49	Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. *Hepatology*, **2020**, 72, 2000-2013	11.2	59
48	A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. *Hepatology*, **2019**, 70, 231-240	11.2	51
47	Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. *Oncotarget*, **2015**, 6, 10102-15	3.3	43
46	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. *International Journal of Cancer*, **2019**, 144, 533-544	7.5	43
45	Adeno-associated virus in the liver: natural history and consequences in tumour development. *Gut*, **2020**, 69, 737-747	19.2	36
44	Polyploidy spectrum: a new marker in HCC classification. *Gut*, **2020**, 69, 355-364	19.2	34
43	ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. *Journal of Hepatology*, **2013**, 59, 1264-70	13.4	31
42	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. *OncoImmunology*, **2013**, 2, e27090	7.2	30
41	Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. *Radiology*, **2020**, 295, 562-571	20.5	30
40	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. *Gut*, **2021**,	19.2	29
39	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. *Journal of Hepatology*, **2018**, 69, 336-344	13.4	28
38	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. *Clinical Cancer Research*, **2019**, 25, 5859-5865	12.9	26

37	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. *Journal of Hepatology*, **2017**, 66, 734-742	13.4	25
36	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. *Hepatology*, **2018**, 68, 964-976	11.2	25
35	Combined hepatocellular-cholangiocarcinoma: An update. *Journal of Hepatology*, **2021**, 74, 1212-1224	13.4	24
34	Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers. *Gut*, **2021**, 70, 1183-1193	19.1	24
33	Development of AI-based pathology biomarkers in gastrointestinal and liver cancer. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 591-592	24.2	23
32	Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. *Journal of Hepatology*, **2018**, 69, 1074-1087	13.4	22
31	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. *Clinical Cancer Research*, **2020**, 26, 4381-4389	12.9	21
30	Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation. *Cancer Imaging*, **2016**, 16, 4	5.6	19
29	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. *Journal of Hepatology*, **2020**, 72, 924-936	13.4	18
28	germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. *OncoImmunology*, **2019**, 8, e1583547	7.2	16
27	BRAF V600E mutational status in bile duct adenomas and hamartomas. *Histopathology*, **2015**, 67, 562-7	7.3	16
26	Ultrasonography of gallbladder abnormalities due to schistosomiasis. *Parasitology Research*, **2016**, 115, 2917-24	2.4	16
25	Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. *European Radiology*, **2019**, 29, 3791-3801	8	14
24	Solitary splenic metastasis from nasopharyngeal carcinoma: a case report and systematic review of the literature. *World Journal of Surgical Oncology*, **2016**, 14, 184	3.4	14
23	Interleukins-17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation. *Hepatology Communications*, **2018**, 2, 329-343	6	12
22	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. *Journal of Hepatology*, **2021**, 74, 1155-1166	13.4	11
21	Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia. *Journal of Inherited Metabolic Disease*, **2018**, 41, 955-963	5.4	10
20	Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. *Liver International*, **2020**, 40, 74-82	7.9	9

19	Impact of hepatobiliary phase liver MRI versus Contrast-Enhanced Ultrasound after an inconclusive extracellular gadolinium-based contrast-enhanced MRI for the diagnosis of benign hepatocellular tumors. *Abdominal Radiology*, **2017**, 42, 825-832	3	8
18	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. *Hepatology*, **2021**, 74, 816-834	11.2	7
17	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.. *Journal of Hepatology*, **2022**,	13.4	6
16	Primary leiomyosarcoma of the liver: Two new cases and a systematic review. *Annals of Hepato-biliary-pancreatic Surgery*, **2020**, 24, 63-67	1.5	5
15	Transcriptomic learning for digital pathology		4
14	Pathologic and molecular features of hepatocellular carcinoma: An update. *World Journal of Hepatology*, **2021**, 13, 393-410	3.4	4
13	Immune profiling of combined hepatocellular-cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. *Clinical Cancer Research*, **2021**,	12.9	3
12	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. *Journal of Hepatology*, **2021**,	13.4	3
11	An Unusual Cause of Cholecystitis. *Gastroenterology*, **2016**, 150, e3-e4	13.3	3
10	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.. *Journal of Hepatology*, **2022**, 76, 1348-1361	13.4	3
9	Bile duct adenoma should not be designated as a reactive process. *Pathology International*, **2015**, 65, 338	1.8	2
8	Artificial intelligence for solid tumour diagnosis in digital pathology. *British Journal of Pharmacology*, **2021**, 178, 4291-4315	8.6	2
7	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.. *Lancet Oncology, The*, **2022**, 23, 161-171	21.7	1
6	REPLY. *Hepatology*, **2021**, 73, 2078-2079	11.2	1
5	Identification of an EML4-ALK rearrangement in an intrahepatic cholangiocarcinoma. *Pathology International*, **2021**, 71, 630-632	1.8	1
4	Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin. *Blood*, **2018**, 132, 4597-4597	2.2	0
3	Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through miR-122 downregulation with increased risk of primary liver cancer initiation.. *International Journal of Biological Sciences*, **2022**, 18, 1944-1960	11.2	0
2	Benign Tumors, Nodules, and Cystic Diseases of the Liver **2017**, 947-976		

1   Histoséminaire « Pathologie tumorale hépatique » : pré-tests. *Annales De Pathologie*, **2021**, 41, 430-433   0.3

1   Histoséminaire « Pathologie tumorale hépatique » : pré-tests. *Annales De Pathologie*, **2021**, 41, 430-433   0.3